Allogene Therapeutics Expands Cemacabtagene Ansegedleucel Phase 2 ALPHA3 Trial to South Korea and Australia

Key Takeaways

• Regulatory authorities in South Korea and Australia have cleared Allogene’s pivotal Phase 2 ALPHA3 study expansion
• The trial evaluates cemacabtagene ansegedleucel (cema-cel) as first-line consolidation treatment for cancer patients
• International expansion accelerates patient enrollment and brings allogeneic CAR-T therapy closer to global markets

---

SOUTH SAN FRANCISCO, Calif. – April 21, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced today that regulatory authorities in South Korea and Australia have approved the expansion of its pivotal Phase 2 ALPHA3 clinical trial, bringing the company’s innovative allogeneic CAR-T therapy to new international markets.

Trial Expansion Details

The ALPHA3 study evaluates cemacabtagene ansegedleucel (cema-cel), Allogene’s lead allogeneic CAR-T candidate, as a first-line consolidation treatment for cancer patients. This regulatory clearance marks a significant milestone in the company’s global development strategy for off-the-shelf CAR-T therapies.

Allogene Therapeutics specializes in developing allogeneic CAR-T (AlloCAR-T) products, which offer potential advantages over traditional autologous CAR-T therapies by providing immediate availability and reduced manufacturing complexity.

Market Impact and Implications

The international expansion of the ALPHA3 trial is expected to accelerate patient enrollment and provide crucial data from diverse patient populations. South Korea and Australia represent key strategic markets with robust regulatory frameworks and growing oncology treatment demands.

Cemacabtagene ansegedleucel represents a new generation of cancer immunotherapy that could transform treatment paradigms by offering patients immediate access to CAR-T therapy without the typical 2-4 week manufacturing wait time associated with personalized treatments.

Clinical Development Progress

The Phase 2 ALPHA3 study focuses on first-line consolidation therapy, positioning cema-cel as a potential standard-of-care treatment option. This approach could significantly impact treatment outcomes by providing enhanced therapeutic intervention at an earlier stage of disease management.

Allogene’s allogeneic approach addresses key limitations of current CAR-T therapies, including manufacturing delays, supply chain challenges, and cost considerations that have historically limited patient access to these breakthrough treatments.

---

Frequently Asked Questions

What does this trial expansion mean for cancer patients?

The expansion to South Korea and Australia increases patient access to potentially life-saving allogeneic CAR-T therapy and accelerates the development timeline for cemacabtagene ansegedleucel, bringing this innovative treatment closer to global availability.

When will cemacabtagene ansegedleucel be available commercially?

The timeline depends on Phase 2 ALPHA3 trial results and subsequent regulatory approvals. The international expansion is expected to accelerate data collection, potentially bringing commercial availability closer, though specific timelines have not been disclosed.

How does allogeneic CAR-T therapy differ from existing treatments?

Unlike autologous CAR-T therapies that require weeks to manufacture from each patient’s cells, allogeneic CAR-T products like cema-cel are pre-manufactured and immediately available, potentially reducing treatment delays and improving patient outcomes.